GERARDO JAVIER FERNANDEZ
Medical Practice in Yorktown Hgts, NY
License number
Pennsylvania MD436064
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Yorktown Hgts, NY 10598
Pennsylvania
Pennsylvania
Personal information
See more information about GERARDO JAVIER FERNANDEZ at radaris.comName
Address
Phone
5125 48Th St #1, Woodside, NY 11377
3531 Crescent St APT 3F, Astoria, NY 11106
3925 29Th St APT 1B, Long Is City, NY 11101
644 W 173Rd St APT C4, New York, NY 10032
9120 116Th St #1, Jamaica, NY 11418
Professional information
Systems And Methods For Treating, Diagnosing And Predicting The Occurrence Of A Medical Condition
US Patent:
2010017, Jul 15, 2010
Filed:
Jul 27, 2009
Appl. No.:
12/462041
Inventors:
Michael Donovan - Cambridge MA, US
Faisal Khan - Fishkill NY, US
Gerardo Fernandez - Yorktown Heights NY, US
Ali Tabesh - New York NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US
Stephen Fogarasi - Pawling NY, US
Yevgen Vengrenyuk - Mamaroneck NY, US
Faisal Khan - Fishkill NY, US
Gerardo Fernandez - Yorktown Heights NY, US
Ali Tabesh - New York NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US
Stephen Fogarasi - Pawling NY, US
Yevgen Vengrenyuk - Mamaroneck NY, US
Assignee:
Aureon Laboratories, Inc. - Yonkers NY
International Classification:
G06K 9/00, G06F 19/00
US Classification:
382133, 702 19
Abstract:
Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.
Systems And Methods For Treating, Diagnosing And Predicting The Occurrence Of A Medical Condition
US Patent:
2010018, Jul 22, 2010
Filed:
Aug 28, 2009
Appl. No.:
12/584048
Inventors:
Michael Donovan - Cambridge MA, US
Faisal Khan - Fishkill NY, US
Jason Alter - Stamford CT, US
Gerardo Fernandez - Yorktown Heights NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Bronxville NY, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - New Rochelle NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US
Faisal Khan - Fishkill NY, US
Jason Alter - Stamford CT, US
Gerardo Fernandez - Yorktown Heights NY, US
Ricardo Mesa-Tejada - Pleasantville NY, US
Douglas Powell - Bronxville NY, US
Valentina Bayer Zubek - Yonkers NY, US
Stefan Hamann - New Rochelle NY, US
Carlos Cordon-Cardo - New York NY, US
Jose Costa - Guilford CT, US
Assignee:
Aureon Laboratories, Inc. - Yonkers NY
International Classification:
G01N 33/53, C12M 1/34
US Classification:
435 721, 4352871
Abstract:
Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.